© 2006 European Society for Medical Oncology
editorial |
On prejudice and facts and choices
1 Department of Oncology and Hematology, Klinikum Oldenburg gGmbH, Oldenburg, Germany
2 Medizinische Klinik I, University Clinic, Dresden, Germany
(E-mail: onkologie@klinikum-oldenburg.de)
| The first 150 words of the full text of this article appear below. |
The use of anticancer agents as oral formulations is likely to increase over the coming years. Most of the new compounds will be developments of targeted agents. Classical anti-neoplastic drugs have been available as oral medications for some time. Some of these compounds are analogues of their i.v. counterparts. When used in combination regimens these agents are always under threat of being substituted by their i.v. sisters, at least if one of the combination partners needs to be given intravenously. The CMF regimen is a prominent example. Instead of giving cyclophosphamide p.o. as in the original schedule, it was often injected together with methotrexate and 5-fluorouracil [1
]. Convenience of application and concern of potential non-compliance may have been reasons for this practice or it was the myth that an injection is always better than any tablet. Cancer patients are considered to be more compliant as they have ‘too much
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J Cassidy In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht Ann. Onc., September 1, 2006; 17(9): 1469 - 1471. [Full Text] [PDF]
|
|